Napo Therapeutics CEO Honored for Rare Disease Advocacy and Plant-Based Innovation
Massimo Radaelli, President and CEO of Napo Therapeutics, has been named CEO of the Year in the Pharmaceutical Industry by European CEO. In a recent interview, Radaelli discussed his lifelong dedication to researching orphan medicines for rare diseases, which affect millions globally despite their individual rarity. He highlighted the strategic partnership between Napo Therapeutics and Jaguar Health, leveraging decades of experience in plant-based prescription medicines. A key focus is crofelemer, the first FDA-approved oral botanical drug derived from the Amazonian Croton lechleri tree. This anti-secretory agent addresses gastrointestinal distress and shows potential for treating conditions like cancer therapy-related diarrhea and rare pediatric disorders such as microvillus inclusion disease (MVID). Radaelli emphasized the importance of empathy, ethics, and sustainable harvesting practices in healthcare innovation. The article underscores the growing momentum of precision medicine and gene therapies in transforming the treatment landscape for patients with high unmet medical needs, positioning Napo Therapeutics as a leader in improving quality of life for those suffering from debilitating gastrointestinal rare diseases.
Wire timeline
Napo Therapeutics CEO Honored for Rare Disease Advocacy and Plant-Based Innovation
Massimo Radaelli, President and CEO of Napo Therapeutics, has been named CEO of the Year in the Pharmaceutical Industry by European CEO. In a recent interview, Radaelli discussed his lifelong dedication to researching orphan medicines for rare diseases, which affect millions globally despite their individual rarity. He highlighted the strategic partnership between Napo Therapeutics and Jaguar Health, leveraging decades of experience in plant-based prescription medicines. A key focus is crofelemer, the first FDA-approved oral botanical drug derived from the Amazonian Croton lechleri tree. This anti-secretory agent addresses gastrointestinal distress and shows potential for treating conditions like cancer therapy-related diarrhea and rare pediatric disorders such as microvillus inclusion disease (MVID). Radaelli emphasized the importance of empathy, ethics, and sustainable harvesting practices in healthcare innovation. The article underscores the growing momentum of precision medicine and gene therapies in transforming the treatment landscape for patients with high unmet medical needs, positioning Napo Therapeutics as a leader in improving quality of life for those suffering from debilitating gastrointestinal rare diseases.
European CEO